Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial

被引：0
|
作者：
Liu, Zengjun
Liu, Mengyao
Xu, Jing
Hu, Wenyu
Zhu, Dongyuan
Tao, Rongjie
Xu, Ni
Zhang, Hui
Li, Minghuan
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Rare Tumors Dept, Jinan, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Rare Tumors Dept, Jinan, Shandong, Peoples R China
[3] Shandong Canc Hosp & Inst, Rare Tumors Dept, Jinan, Peoples R China
[4] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[5] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol & Radiol, Jinan, Shandong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11553
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy Profile of TQB-2450 Alone/with Anlotinib in Previously-Treated Advanced NSCLC: A Phase IB Single-Arm Trial
    Han, B.
    Zhang, W.
    Shi, C.
    Chu, T.
    Zhong, H.
    Zhang, Y.
    Lou, Y.
    Dong, Y.
    Qian, F.
    Zhou, W.
    Chen, Y.
    Yang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S346 - S346
  • [22] Efficacy and safety of anlotinib combined with liposomal doxorubicin in first-line treatment of advanced soft-tissue sarcoma.
    Sun, Xin
    Guo, Wei
    Zhang, Ranxin
    Xie, Lu
    Xu, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC-A single-arm, multicenter, phase II clinical trial.
    Yan Jin
    Zhang Li
    Jin Yongdong
    Han Yunwei
    Sun Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [24] Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II
    Liu, Xin
    Jiang, Shiyu
    Wang, Huijie
    Wu, Xianghua
    Yan, Wangjun
    Chen, Yong
    Xu, Yu
    Wang, Chunmeng
    Yao, Weiqiang
    Wang, Jian
    Yu, Lin
    Miao, Jiashun
    Chen, Hao
    Xia, Jing
    Huang, Mengli
    Zhang, Xiaowei
    Luo, Zhiguo
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5280 - 5289
  • [25] Efficacy and safety of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma: A multicenter, single armed, phase 1b trial.
    Liu, Jiayong
    Fan, Zhengfu
    Guo, Wei
    Gao, Tian
    Li, Shu
    Xu, Jie
    Bai, Chujie
    Xue, Ruifeng
    Zhang, Lu
    Xie, Lu
    Tan, Zhichao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in Chemotherapy-Ineligible Patients: An Open-Label, Single-Arm, Phase 2 Clinical Trial
    Li, Tao
    Dong, Ying
    Wei, Yongzhong
    Wang, Shoufeng
    Liu, Yunxia
    Chen, Jia
    Xiong, Wenhua
    Lin, Nong
    Huang, Xin
    Liu, Meng
    Yan, Xiaobo
    Ye, Zhaoming
    Li, Binghao
    CLINICAL CANCER RESEARCH, 2024, 30 (19) : 4310 - 4317
  • [27] Efficacy and safety of anlotinib in advanced soft tissue sarcoma: results from one of multi-centers in a phase IIB trial (ALTER0203).
    Tang, Lina
    Wang, Yonggang
    Zhang, Jianjun
    Yu, Wenxi
    Huang, Yujing
    Yao, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Efficacy of Anlotinib combined with S-1 as the second-line treatment for advanced soft tissue sarcoma
    Tie, Xiao-Jing
    Yang, Chen-Guang
    Gao, Yao-Hong
    Liu, Pei-Jie
    ASIAN JOURNAL OF SURGERY, 2023, 46 (02) : 1050 - 1051
  • [29] Sintilimab plus anlotinib in patients with advanced sarcomas (SINANLOSARC): A single-centre, single-arm, phase II trial
    Liu, Z.
    Liu, M.
    Xu, J.
    Fu, H.
    Zhu, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S1038 - S1038
  • [30] Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
    Tan, Zhichao
    Wu, Yan
    Fan, Zhengfu
    Gao, Tian
    Guo, Wei
    Bai, Chujie
    Xue, Ruifeng
    Li, Shu
    Zhang, Lu
    Wang, Xinyu
    Jia, Ling
    Liu, Jiayong
    CLINICAL CANCER RESEARCH, 2024, 30 (24) : 5577 - 5583
12345